Showing 6,961 - 6,980 results of 74,781 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 1.38s Refine Results
  1. 6961

    R346K Mutation in the <i>Mu</i> Variant of SARS-CoV‑2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study by Filip Fratev (1799740)

    Published 2022
    “…The <i>Mu</i> variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the World Health Organization (WHO) but limited data are available at the moment. …”
  2. 6962

    R346K Mutation in the <i>Mu</i> Variant of SARS-CoV‑2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study by Filip Fratev (1799740)

    Published 2022
    “…The <i>Mu</i> variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the World Health Organization (WHO) but limited data are available at the moment. …”
  3. 6963
  4. 6964
  5. 6965
  6. 6966
  7. 6967
  8. 6968

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  9. 6969

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  10. 6970

    DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  11. 6971

    DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  12. 6972

    DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  13. 6973
  14. 6974

    Characteristics of treatment modality. by Adekunle Emmanuel Sajo (15285520)

    Published 2025
    “…The median time to completion of radiotherapy treatment was higher among those who received primary radiotherapy as compared to those who received adjuvant treatment, 51.5 vs 46 days, p 0.039. The annual average age decreased from 56 years to as low as 40 years, a mean difference of 16 years, p 0.012.…”
  15. 6975

    Demographic and clinical characteristics. by Adekunle Emmanuel Sajo (15285520)

    Published 2025
    “…The median time to completion of radiotherapy treatment was higher among those who received primary radiotherapy as compared to those who received adjuvant treatment, 51.5 vs 46 days, p 0.039. The annual average age decreased from 56 years to as low as 40 years, a mean difference of 16 years, p 0.012.…”
  16. 6976

    Poly(ionic liquid) Electrolytes for a Switchable Silver Mirror by Xiao Hou (3228048)

    Published 2019
    “…These findings were used to guide fabrication of a 50 cm<sup>2</sup> mirror dynamic window and flexible display. …”
  17. 6977
  18. 6978

    S1 Data - by Jordan A. Gunning (18143970)

    Published 2024
    “…Specifically, total immune cells (CD45+) decrease at days 2 and 5 following IR, macrophages (F4/80+CD11b+) decrease at day 2 and 5 and increase at day 30, while neutrophils (Ly6G+CD11b+) significantly increase at day 30 following IR. …”
  19. 6979

    Rec12-DNA Covalent Linkages Are Readily Detectable in <i>rad50<sup>+</sup></i> Strains. by Randy W. Hyppa (269310)

    Published 2008
    “…The 5 h <i>rad50S</i> DNA shows a much stronger enrichment (ratio of PCR product from the ChIP to that from the WCE) as a result of Rec12 not being removed from the DNA ends in that strain. …”
  20. 6980